These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20529284)

  • 21. Cilostazol: a new drug in the treatment intermittent claudication.
    Kumar M; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):181-5. PubMed ID: 18221117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of relationship between gait parameters and physical function in peripheral arterial disease.
    Scherer SA; Hiatt WR; Regensteiner JG
    J Vasc Surg; 2006 Oct; 44(4):782-8. PubMed ID: 17012002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gait kinematics and kinetics are affected more by peripheral arterial disease than by age.
    Myers SA; Applequist BC; Huisinga JM; Pipinos II; Johanning JM
    J Rehabil Res Dev; 2016; 53(2):229-38. PubMed ID: 27149635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A biomechanical perspective on walking in patients with peripheral artery disease.
    Bapat GM; Bashir AZ; Malcolm P; Johanning JM; Pipinos II; Myers SA
    Vasc Med; 2023 Feb; 28(1):77-84. PubMed ID: 36759931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
    Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP
    Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intralimb coordination variability in peripheral arterial disease.
    Crowther RG; Spinks WL; Leicht AS; Quigley F; Golledge J
    Clin Biomech (Bristol, Avon); 2008 Mar; 23(3):357-64. PubMed ID: 18061322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy for peripheral arterial disease: emerging therapeutic options.
    Jaff MR
    Angiology; 2002; 53(6):627-33. PubMed ID: 12463615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical management of peripheral arterial disease.
    Creager MA
    Cardiol Rev; 2001; 9(4):238-45. PubMed ID: 11405904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gait variability is affected more by peripheral artery disease than by vascular occlusion.
    Rahman H; Pipinos II; Johanning JM; Myers SA
    PLoS One; 2021; 16(3):e0241727. PubMed ID: 33788839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
    Dawson DL; Cutler BS; Hiatt WR; Hobson RW; Martin JD; Bortey EB; Forbes WP; Strandness DE
    Am J Med; 2000 Nov; 109(7):523-30. PubMed ID: 11063952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
    Guest JF; Davie AM; Clegg JP
    Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of claudication pain on temporal and spatial gait measures during self-paced ambulation.
    Gardner AW; Montgomery PS; Ritti-Dias RM; Forrester L
    Vasc Med; 2010 Feb; 15(1):21-6. PubMed ID: 19783569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gait deficiencies associated with peripheral artery disease are different than chronic obstructive pulmonary disease.
    McCamley JD; Pisciotta EJ; Yentes JM; Wurdeman SR; Rennard SI; Pipinos II; Johanning JM; Myers SA
    Gait Posture; 2017 Sep; 57():258-264. PubMed ID: 28683417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
    Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
    Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effects of cilostazol and other therapies for intermittent claudication.
    Dawson DL
    Am J Cardiol; 2001 Jun; 87(12A):19D-27D. PubMed ID: 11434896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-curve rocker-soled shoes and gait adaptations to intermittent claudication pain: A randomised crossover trial.
    Jordan AR; Tew GA; Hutchins SW; Shalan A; Cook L; Thompson A
    Gait Posture; 2019 Jan; 67():31-36. PubMed ID: 30265963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amino acids stimulate leg muscle protein synthesis in peripheral arterial disease.
    Killewich LA; Tuvdendorj D; Bahadorani J; Hunter GC; Wolfe RR
    J Vasc Surg; 2007 Mar; 45(3):554-9; discussion 559-60. PubMed ID: 17321342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.